These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 26925822)
81. Cyclosporine-A for severe childhood atopic dermatitis: clinical experience on efficacy and safety profile. Sarıcaoğlu H; Yazici S; Zorlu Ö; Bülbül Başkan E; Aydoğan K Turk J Med Sci; 2018 Oct; 48(5):933-938. PubMed ID: 30384556 [TBL] [Abstract][Full Text] [Related]
82. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Markowitz J; Grancher K; Mandel F; Daum F Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272 [TBL] [Abstract][Full Text] [Related]
83. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Proudfoot LE; Powell AM; Ayis S; Barbarot S; Baselga Torres E; Deleuran M; Fölster-Holst R; Gelmetti C; Hernández-Martin A; Middelkamp-Hup MA; Oranje AP; Logan K; Perkin M; Patrizi A; Rovatti G; Schofield O; Spuls P; Svensson Å; Vestergaard C; Wahlgren CF; Schmitt J; Flohr C; Br J Dermatol; 2013 Oct; 169(4):901-9. PubMed ID: 23855450 [TBL] [Abstract][Full Text] [Related]
84. Systemic treatment for severe atopic dermatitis in children: a case series. Cheirif-Wolosky O; Elizalde-Jiménez IG; Romero MTG Bol Med Hosp Infant Mex; 2022; 79(5):310-317. PubMed ID: 36264887 [TBL] [Abstract][Full Text] [Related]
85. Cyclosporin is safe and effective in severe atopic dermatitis of childhood. Report of three cases. Leonardi S; Marchese G; Rotolo N; Miraglia Del Giudice M; La Rosa M Minerva Pediatr; 2004 Apr; 56(2):231-7. PubMed ID: 15249910 [TBL] [Abstract][Full Text] [Related]
86. Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies. Marko M; Pawliczak R Expert Rev Clin Immunol; 2021 Jun; 17(6):619-627. PubMed ID: 33866905 [No Abstract] [Full Text] [Related]
87. Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial. Jin SY; Lim WS; Sung NH; Cheong KA; Lee AY Dermatol Ther; 2015; 28(1):44-51. PubMed ID: 25113885 [TBL] [Abstract][Full Text] [Related]
88. [How should severe and chronic atopic dermatitis in children be managed?]. Bodemer C Ann Dermatol Venereol; 2005 Jan; 132 Spec No 1():1S121-30. PubMed ID: 15984304 [TBL] [Abstract][Full Text] [Related]
90. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). Couselo-Rodríguez C; Batalla A; Carrascosa JM; Chicharro P; González-Quesada A; de la Cueva P; Giménez-Arnau AM; Gilaberte Y; Rodríguez-Serna M; Montero-Vilchez T; Ruiz-Villaverde R; Elosua-González M; Silvestre-Salvador JF; Munera-Campos M; Sánchez-Pérez J; Carretero G; Mauleón-Fernández C; Curto-Barredo L; Ballano-Ruiz A; Botella-Estrada R; Arias-Santiago S; Navarro-Triviño FJ; Roustan-Gullón G; Betlloch I; Del Alcázar E; Abalde-Pintos MT; Suárez-Perez J; García-Doval I; Descalzo MÁ; Flórez Á Actas Dermosifiliogr; 2024 Apr; 115(4):341-346. PubMed ID: 37482292 [TBL] [Abstract][Full Text] [Related]
91. Use of cyclosporine in children and adolescents with moderate to severe atopic dermatitis: clinical experience in a tertiary Hospital. Proença CC; Mayor SAS; Ragazzo TS; Munhoz SDG; Pires CG An Bras Dermatol; 2023; 98(4):526-528. PubMed ID: 36973096 [No Abstract] [Full Text] [Related]
92. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. Wollenberg A; Kinberger M; Arents B; Aszodi N; Avila Valle G; Barbarot S; Bieber T; Brough HA; Calzavara Pinton P; Christen-Zäch S; Deleuran M; Dittmann M; Dressler C; Fink-Wagner AH; Fosse N; Gáspár K; Gerbens L; Gieler U; Girolomoni G; Gregoriou S; Mortz CG; Nast A; Nygaard U; Redding M; Rehbinder EM; Ring J; Rossi M; Serra-Baldrich E; Simon D; Szalai ZZ; Szepietowski JC; Torrelo A; Werfel T; Flohr C J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1409-1431. PubMed ID: 35980214 [TBL] [Abstract][Full Text] [Related]
93. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. Papp KA; Toth D; Rosoph L BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371 [TBL] [Abstract][Full Text] [Related]